Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Riluzole
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Brain Trust Receives Approval for Trials Targeting CNS Diseases with Intrathecal Delivery
Details : IT Riluzole (riluzole)is a intrathecally delivered glutamate antagonist. It is being evaluated for the treatment of amyotrophic lateral sclerosis & other central nervous system diseases.
Brand Name : IT-Riluzole
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 25, 2024
Lead Product(s) : Riluzole
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?